Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

4.21USD
1:30am IST
Change (% chg)

$0.12 (+2.93%)
Prev Close
$4.09
Open
$4.08
Day's High
$4.24
Day's Low
$3.99
Volume
314,916
Avg. Vol
436,124
52-wk High
$13.71
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Dynavax Technologies Announces Proposed Public Offering Of Common Stock, Non-Voting Preferred Stock And Warrants To Purchase Common Stock
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK, NON-VOTING PREFERRED STOCK AND WARRANTS TO PURCHASE COMMON STOCK.DYNAVAX TECHNOLOGIES CORP - INTENDS TO OFFER AND SELL AN AGGREGATE OF UP TO $60.0 MILLION OF SHARES OF ITS COMMON STOCK.DYNAVAX TECHNOLOGIES CORP - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ACTIVITIES ASSOCIATED WITH ONGOING COMMERCIALIZATION OF HEPLISAV-B.  Full Article

Dynavax Announces Strategic Restructuring To Focus On Its Vaccine Business
Friday, 24 May 2019 

May 23 (Reuters) - Dynavax Technologies Corp ::DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS VACCINE BUSINESS.DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS VACCINE BUSINESS.DYNAVAX TECHNOLOGIES CORP - COMPANY WILL ALIGN ITS RESOURCES TO FOCUS ON HEPLISAV-B COMMERCIALIZATION.DYNAVAX TECHNOLOGIES CORP - EDDIE GRAY, CEO, TO RETIRE.DYNAVAX TECHNOLOGIES CORP - EDDIE GRAY, CEO, TO RETIRE.DYNAVAX TECHNOLOGIES CORP - WILL EXPLORE STRATEGIC ALTERNATIVES FOR ITS IMMUNO-ONCOLOGY PROGRAMS.DYNAVAX TECHNOLOGIES CORP - WORKFORCE REDUCTION IS EXPECTED TO REDUCE COMPENSATION AND BENEFITS COST BY APPROXIMATELY $16 MILLION DOLLARS ANNUALLY.DYNAVAX TECHNOLOGIES CORP - WILL CONDUCT A SEARCH FOR COMPANY'S NEXT CEO AND WILL CONSIDER BOTH INTERNAL AND EXTERNAL CANDIDATES..DYNAVAX TECHNOLOGIES CORP - IS ELIMINATING APPROXIMATELY 82 CURRENT POSITIONS.DYNAVAX TECHNOLOGIES - RESTRUCTURING COSTS AND RETIREMENT COSTS, SEVERANCE COSTS, ARE EXPECTED TO BE APPROXIMATELY $5.5 MILLION.DYNAVAX TECHNOLOGIES - IS ELIMINATING ABOUT 37% OF ITS CURRENT U.S. WORKFORCE.DYNAVAX - WILL BE RESPONSIBLE FOR SOME WIND-DOWN COSTS, COMMITTED CONTRACTUAL COSTS FOR IMMUNO-ONCOLOGY PROGRAMS THAT WILL RUN THROUGH Q2 NEXT YEAR.DYNAVAX TECHNOLOGIES - ESTIMATES OPERATING EXPENDITURES RELATED TO EXTERNAL ONCOLOGY COSTS WILL BE REDUCED BY ABOUT $8 MILLION PER QUARTER VERSUS MARCH QUARTER.DYNAVAX TECHNOLOGIES - AS OF MARCH 31, REPORTED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $183.2 MILLION..  Full Article

Dynavax Reports Q1 Loss Per Share $0.62
Thursday, 9 May 2019 

May 8 (Reuters) - Dynavax Technologies Corp ::DYNAVAX ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.65 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $183.2 MILLION AT MARCH 31, 2019.  Full Article

Dynavax Technologies Expects Sales Of Heplisav-B For Quarter Ended Dec 31 To Be No Less Than $3.7 Mln
Saturday, 12 Jan 2019 

Jan 11 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES - EXPECTS SALES OF HEPLISAV-B FOR FISCAL QUARTER ENDED DEC 31, 2018 TO BE NO LESS THAN $3.7 MILLION.  Full Article

Sam's Club And Dynavax Technologies Announce Collaboration To Make Hepatitis B Vaccine
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Dynavax Technologies Corp ::SAM’S CLUB AND DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCE COLLABORATION TO MAKE HEPLISAV-B® [HEPATITIS B VACCINE (RECOMBINANT), ADJUVANTED] AVAILABLE TO SAM’S CLUB PATIENTS.DYNAVAX TECHNOLOGIES - CO, SAM'S CLUB TEAMED UP TO INTRODUCE HEPLISAV-B INTO SAM'S CLUB RETAIL PHARMACIES NATION-WIDE IN U.S..  Full Article

Dynavax Reports Q3 Loss Per Share Of $0.65
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS, PROGRESS ON HEPLISAV-B LAUNCH, AND UPDATED SD-101 DATA IN THREE PATIENT POPULATIONS.Q3 LOSS PER SHARE $0.65.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.Q3 SALES $1.5 MILLION.Q3 REVENUE VIEW $3.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Healthcor Management LP Reports 5.5 Pct Passive Stake In Dynavax Technologies Corp As Of October 1
Friday, 12 Oct 2018 

Oct 11 (Reuters) - Dynavax Technologies Corp ::HEALTHCOR MANAGEMENT LP REPORTS 5.5 PERCENT PASSIVE STAKE IN DYNAVAX TECHNOLOGIES CORP AS OF OCTOBER 1 - SEC FILING.  Full Article

Dynavax Qtrly Loss Per Share $0.45
Thursday, 8 Mar 2018 

March 8 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS.DYNAVAX TECHNOLOGIES CORP - QTRLY LOSS PER SHARE $0.45.  Full Article

Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Dynavax Technologies Corp :Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults.Dynavax Technologies Corp - ‍expects to commercially launch Heplisav-B in United States in Q1 of 2018​.  Full Article

Dynavax reports Q3 loss per share $0.38
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Dynavax Technologies Corp :Dynavax reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - Qtrly total revenue $53,000 versus $162,000‍​.Dynavax Technologies - ‍Cash, cash equivalents & marketable securities were $191.7 million at Sept 30, 2017 compared to $81.4 million at Dec 31, 2016​.  Full Article